Monash IVF Group Ltd (MVF) AI Stock Analysis

• Market Cap: AU$268.85M
• Dividend Yield: 6%
• Average Volume (3M): 2.18M
• Price to Earnings (P/E): 10.7
• Beta (1Y): 0.87
• Revenue Growth: 6.65%
• EPS Growth: N/A
• Country: AU
• Employees: 997
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 389,634,830
• 10 Day Avg. Volume: 1,374,502
• 30 Day Avg. Volume: 2,181,726
• PEG Ratio: -0.02
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.01
• P/FCF Ratio: 588.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.81
• Price Target Upside: -4.71% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: AU$1.00 ▲(17.65% Upside)

Monash IVF Group Ltd's strong valuation metrics, including a low P/E ratio and high dividend yield, are the most significant strengths. However, the overbought technical indicators and weak cash flow position present notable risks. The absence of recent earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

The strong revenue growth indicates robust demand for MVF's services, suggesting a solid market position and potential for continued expansion.

Profitability

Healthy profit margins reflect efficient operations and pricing power, which can sustain long-term profitability and shareholder value.

Stable Balance Sheet

A stable balance sheet with moderate leverage enhances financial stability, providing flexibility for strategic investments and growth.

Negative Factors

Cash Flow Weakness

Weak free cash flow generation can limit the company's ability to invest in growth opportunities and meet financial obligations, posing a risk to long-term operations.

Operating Cash Flow Challenges

Low conversion of income into cash suggests potential inefficiencies in operations, which could impact liquidity and financial health over time.

Volatility in Margins

Volatility in margins indicates potential instability in cost management or pricing strategy, which could affect profitability consistency.

Monash IVF Group Ltd Business Overview & Revenue Model

Company Description

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic and IVF treatment services. The company was incorporated in 2014 and is based in Richmond, Australia.

How the Company Makes Money

Monash IVF Group Ltd generates revenue primarily through the provision of fertility treatment services. Key revenue streams include fees for IVF procedures, consultations, and related medical services, which are often covered partially or fully by private health insurance. The company also earns revenue from genetic testing services and cryopreservation procedures. Significant partnerships with healthcare providers and insurance companies enhance MVF's market reach and patient access, contributing to its earnings. Furthermore, the company may engage in research and development initiatives, which can lead to innovative services and additional revenue opportunities.

Monash IVF Group Ltd Financial Statement Overview

Summary

Monash IVF Group Ltd demonstrates strong revenue growth and profitability with a stable balance sheet. However, the cash flow statement highlights concerns, particularly in free cash flow generation, which needs improvement to enhance overall financial health.

Income Statement

Monash IVF Group Ltd has demonstrated strong revenue growth over the years, with a significant increase of 74.5% in the latest year. The company maintains a healthy gross profit margin of 33.2% and a net profit margin of 9.2%, indicating solid profitability. However, the EBIT and EBITDA margins have shown some volatility, with a notable improvement in the latest year. Overall, the income statement reflects a positive growth trajectory with strong revenue and profit margins.

Balance Sheet

The balance sheet of Monash IVF Group Ltd shows a moderate debt-to-equity ratio of 0.73, indicating a balanced approach to leveraging. The return on equity stands at 10.2%, reflecting efficient use of equity to generate profits. The equity ratio is stable, suggesting a solid capital structure. While the company has increased its debt levels, the overall financial stability remains intact.

Cash Flow

The cash flow statement reveals a significant decline in free cash flow growth, with a decrease of 96.4% in the latest year. The operating cash flow to net income ratio is relatively low at 0.21, indicating potential challenges in converting income into cash. However, the company has maintained positive operating cash flow, which is a positive sign. Overall, the cash flow position shows some weaknesses that need to be addressed.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	271.92M	271.92M	254.96M	213.59M	192.29M	183.60M
Gross Profit	90.31M	90.31M	85.50M	63.41M	57.22M	57.66M
EBITDA	53.01M	53.01M	10.78M	48.49M	43.16M	51.21M
Net Income	25.01M	25.01M	-6.53M	21.84M	18.41M	25.15M
Balance Sheet
Total Assets	492.61M	492.61M	508.47M	421.89M	387.10M	356.17M
Cash, Cash Equivalents and Short-Term Investments	9.43M	9.43M	11.33M	8.01M	7.87M	8.76M
Total Debt	180.31M	180.31M	135.37M	100.04M	77.23M	45.99M
Total Liabilities	242.19M	242.19M	261.81M	146.82M	117.20M	87.73M
Stockholders Equity	246.28M	246.28M	241.91M	273.20M	267.92M	266.19M
Cash Flow
Free Cash Flow	468.00K	468.00K	31.70M	10.16M	19.51M	33.30M
Operating Cash Flow	12.90M	12.90M	52.52M	37.95M	31.28M	43.25M
Investing Cash Flow	-17.43M	-17.43M	-38.80M	-40.51M	-15.16M	-11.21M
Financing Cash Flow	6.68M	2.67M	-10.39M	1.51M	-17.02M	-38.35M

Monash IVF Group Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Positive. The current price of 0.85 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.70, and above the 200-day MA of 0.81, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 69.62 is Neutral, neither overbought nor oversold. The STOCH value of 87.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVF.

Monash IVF Group Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	71 Outperform	AU$524.72M	15.63	18.59%	4.28%	6.73%	37.16%
MVF	67 Neutral	AU$268.85M	10.75	10.25%	6.00%	6.65%	―
SHL	64 Neutral	AU$10.27B	19.43	6.32%	4.59%	9.44%	-0.37%
IDX	55 Neutral	AU$977.07M	172.37	0.94%	2.46%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	50 Neutral	€635.37M	-1.21	-67.21%	―	-23.02%	33.11%

Monash IVF Group Ltd Corporate Events

Monash IVF Group Appoints New CEO to Lead Strategic Focus

Monash IVF Group Ltd has appointed Dr. Victoria Atkinson as the new Managing Director and CEO, effective from May 18, 2026. Dr. Atkinson brings over 30 years of experience in healthcare leadership, previously serving as Chief Medical Officer at Healthscope. Her appointment is expected to enhance the company’s focus on clinical and financial strategies, benefiting its stakeholders, including patients and doctors. The company is also in the process of finding a new Chief Financial Officer as Mr. Andrew MacLachlan concludes his interim role.

The most recent analyst rating on (AU:MVF) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Appoints Dr. Dwayne Crombie to Board

Monash IVF Group Ltd has appointed Dr. Dwayne Crombie as an Independent Non-Executive Director, effective from 24 November 2025. Dr. Crombie brings extensive experience from his career in healthcare across New Zealand and Australia, including senior roles at Bupa and governance positions in healthcare organizations. His appointment is expected to enhance the strategic capabilities of the Monash IVF Group Board, potentially impacting the company’s operations and positioning within the healthcare industry.

The most recent analyst rating on (AU:MVF) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Announces Hybrid 2025 AGM

Monash IVF Group Ltd has announced its 2025 Annual General Meeting (AGM), scheduled for November 20, 2025, which will be held as a hybrid event allowing both in-person and virtual participation. The AGM documents, including the Notice of Meeting and Proxy Form, are available on the company’s website, and shareholders are encouraged to submit questions in advance to facilitate a comprehensive discussion during the meeting.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Announces Cessation of Performance Rights

Monash IVF Group Ltd announced the cessation of 2,564,204 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, particularly in terms of employee incentives and shareholder value.

The most recent analyst rating on (AU:MVF) stock is a Hold with a A$0.77 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Releases 2025 Corporate Governance Statement

Monash IVF Group Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its management and oversight practices. This announcement underscores the company’s dedication to maintaining high governance standards, which is crucial for its stakeholders and market reputation.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Ltd Releases FY25 Results Presentation

Monash IVF Group Ltd has released its FY25 results presentation, providing a general overview of its activities and financial performance. The presentation includes forward-looking statements and non-IFRS measures such as EBITDA and Underlying NPAT, which are used by management to assess business performance. The release highlights the uncertainties and risks associated with future outcomes and emphasizes that past performance is not indicative of future results, impacting stakeholders’ expectations and investment decisions.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Completes Review of Clinic Incidents

Monash IVF Group Ltd has completed an Independent Review of incidents at its Brisbane and Clayton clinics, which involved non-standard IVF treatments and were unrelated. The review identified human error and IT system limitations as causes. The company has implemented many recommendations from the review and additional safeguards to prevent future occurrences, with no expected material financial impact. The company remains committed to patient care and safety.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.